Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 222

The DOI matches its Crossref record.

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

Open access
Vallet, H., Riviere, S., Sanna, A., Deroux, A., Moulis, G., Addimanda, O., Salvarani, C., Lambert, M., Bielefeld, P., Seve, P., Sibilia, J., Pasquali, Jl, Fraison, Jb, Marie, I., Perard, L., Bouillet, L., Cohen, F., Sene, D., Schoindre, Y., Lidove, O., Le Hoang, P., Hachulla, E., Fain, O., Mariette, X., Papo, T., Wechsler, B., Bodaghi, B., Rigon, M.Resche, Cacoub, P., Saadoun, D. · 2015 · Journal of Autoimmunity

Abstract

OBJECTIVE To report the efficacy and safety of anti-TNF agents in patients with severe and/or refractory manifestations of Behçet's disease (BD). METHODS We performed a multicenter study of main characteristics and outcomes of anti-TNF alpha treatments [mainly infliximab (62%), and adalimumab (30%)] in 124 BD patients [48% of men; median age of 33.5 (28-40) years]. RESULTS Overall response (i.e. complete and partial) rate was 90.4%. Clinical responses were observed in 96.3%, 88%, 70%, 77.8%, 92.3% and 66.7% of patients with severe and/or refractory ocular, mucocutaneous, joint, gastro-intestinal manifestations, central nervous system manifestations and cardiovascular manifestations, respectively. No significant difference was found with respect to the efficacy of anti-TNF used as monotherapy or in association with an immunosuppressive agent. The incidence of BD flares/patient/year was significantly lower during anti-TNF treatment (0.2 ± 0.5 vs 1.7 ± 2.4 before the use of anti-TNF, p < 0.0001). The prednisone dose was significantly reduced at 6 and 12 months (p < 0.0001). In multivariate analysis, retinal vasculitis was negatively associated with complete response to anti-TNF (OR = 0.33 [0.12-0.89]; p = 0.03). The efficacy and relapse free survival were similar regardless of the type of anti-TNF agent used. After a median follow-up of 21 [7-36] months, side effects were reported in 28% of patients, including infections (16.3%) and hypersensitivity reactions (4.1%). Serious adverse events were reported in 13% of cases. CONCLUSION Anti-TNF alpha therapy is efficient in all severe and refractory BD manifestations. Efficacy appears to be similar regardless of the anti-TNF agent used (infliximab or adalimumab).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaut.2015.06.005

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 222

Metadata

Authors
Vallet, H., Riviere, S., Sanna, A., Deroux, A., Moulis, G., Addimanda, O., Salvarani, C., Lambert, M., Bielefeld, P., Seve, P., Sibilia, J., Pasquali, J., Fraison, J., Marie, I., Perard, L., Bouillet, L., Cohen, F., Sene, D., Schoindre, Y., Lidove, O., Le Hoang, P., Hachulla, E., Fain, O., Mariette, X., Papo, T., Wechsler, B., Bodaghi, B., Rigon, M. R., Cacoub, P., & Saadoun, D.
Venue
Journal of Autoimmunity
Publisher
Elsevier BV
Published
2015-08
Volume
62
Pages
67-74
ISSN
0896-8411 (ISSN-L)
OpenAlex
W998070158
Cited by
222
References
0
FWCI
20.55
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. https://app.cochat.ai/papers/10.1016/j.jaut.2015.06.005
The paper
Vallet, H., Riviere, S., Sanna, A., Deroux, A., Moulis, G., Addimanda, O., Salvarani, C., Lambert, M., Bielefeld, P., Seve, P., Sibilia, J., Pasquali, J., Fraison, J., Marie, I., Perard, L., Bouillet, L., Cohen, F., Sene, D., Schoindre, Y., . . . Saadoun, D. (2015). Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. Journal of Autoimmunity. https://doi.org/10.1016/j.jaut.2015.06.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.